The guideline authors developed more than 10 recommendations with the goal of promoting high-quality, high-value, evidence-based care for adult patients with moderate to severe ulcerative colitis.
XELJANZ XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
At the Advances in Inflammatory Bowel Diseases Regional in Chicago, Illinois, David T. Rubin, MD, from The University of Chicago, highlights the recent and emerging therapies in ulcerative colitis, as well...
In the longest vedolizumab continuous treatment study to date, GEMINI LTS provided insight on the long-term safety and efficacy of vedolizumab use in ulcerative colitis and Crohn disease. Final results were...
The American Gastroenterological Association has published new recommendations on which therapies are best for the management of mild-to-moderate ulcerative colitis.
Reported prevalence rates of IBS-like symptoms in patients with quiescent ulcerative colitis vary significantly. In a new study, researchers sought to examine these rates and the effects of ongoing...
Previous research has suggested that certain drugs are safe and effective for the short-term treatment of steroid-refractory acute severe ulcerative colitis, but less is known about the long-term effects of...
Previous evidence has suggested that perioperative vedolizumab use is associated with short-term postoperative infectious complications in patients with ulcerative colitis who undergo colectomy.
